174 related articles for article (PubMed ID: 19148563)
1. LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Kruk M; Ralston SH; Albagha OM
Calcif Tissue Int; 2009 Mar; 84(3):171-9. PubMed ID: 19148563
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein receptor-related protein 5 polymorphisms are associated with bone mineral density in Greek postmenopausal women: an interaction with calcium intake.
Stathopoulou MG; Dedoussis GV; Trovas G; Katsalira A; Hammond N; Deloukas P; Lyritis GP
J Am Diet Assoc; 2010 Jul; 110(7):1078-83. PubMed ID: 20630166
[TBL] [Abstract][Full Text] [Related]
4. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.
Markatseli AE; Hatzi E; Bouba I; Georgiou I; Challa A; Tigas S; Tsatsoulis A
Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men.
Kiel DP; Ferrari SL; Cupples LA; Karasik D; Manen D; Imamovic A; Herbert AG; Dupuis J
Bone; 2007 Mar; 40(3):587-96. PubMed ID: 17137849
[TBL] [Abstract][Full Text] [Related]
6. Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptor-related protein 5 gene (LRP5) with bone mineral density in adult Japanese women.
Ezura Y; Nakajima T; Urano T; Sudo Y; Kajita M; Yoshida H; Suzuki T; Hosoi T; Inoue S; Shiraki M; Emi M
Bone; 2007 Apr; 40(4):997-1005. PubMed ID: 17306638
[TBL] [Abstract][Full Text] [Related]
7. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
[TBL] [Abstract][Full Text] [Related]
10. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
12. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
13. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
15. Relationship between changes of bone mineral density over seven years and A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene or lifestyle factors in Japanese female workers.
Funakoshi Y; Omori H; Yada H; Katoh T
Asia Pac J Clin Nutr; 2010; 19(4):534-9. PubMed ID: 21147715
[TBL] [Abstract][Full Text] [Related]
16. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
18. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.
Mencej-Bedrac S; Prezelj J; Kocjan T; Komadina R; Marc J
Calcif Tissue Int; 2009 Dec; 85(6):501-6. PubMed ID: 19898734
[TBL] [Abstract][Full Text] [Related]
19. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Zhou PR; Liu HJ; Liao EY; Zhang ZL; Chen DC; Liu J; Wu W; Xing XP; Xia WB; Xu L; Li M
Pharmacogenomics; 2014 Apr; 15(6):821-31. PubMed ID: 24897288
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal Maya-Mestizo women.
Canto-Cetina T; Polanco Reyes L; González Herrera L; Rojano-Mejía D; Coral-Vázquez RM; Coronel A; Canto P
Am J Hum Biol; 2013; 25(6):713-8. PubMed ID: 24130145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
